Trials / Completed
CompletedNCT03537742
Cardiac Allograft Vasculopathy Inhibition With Alirocumab
PCSK9 Inhibition After Heart Transplantation
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 114 (actual)
- Sponsor
- Stanford University · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The focus of this study is to test the safety and efficacy of the PCSK9 inhibitor, alirocumab when administered early after heart transplantation (HT).The main objective of this project is to test the safety and impact on cardiac allograft vasculopathy (CAV) of alirocumab when given early after HT.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | alirocumab | alirocumab 150mg Subcutaneous |
| BIOLOGICAL | placebo | placebo to match alirocumab |
Timeline
- Start date
- 2019-05-13
- Primary completion
- 2025-07-11
- Completion
- 2025-07-11
- First posted
- 2018-05-25
- Last updated
- 2026-03-17
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03537742. Inclusion in this directory is not an endorsement.